SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · Q3 rev -48% YoY; Heron deal

CorMedix Inc. · DEFA14A filed Nov 13, 2026 at 20:56 ET

At the news

BEARISHIMPACT 6/10

DEFA14A filed Nov 13, 2026 at 20:56 ET

CorMedix reported Q3 2026 consolidated revenue of $54.5 million (down 48% YoY from $104.3M due to the DefenCath post-TDAPA transition) and a GAAP net loss of $14.7 million vs. net income of $108.6M in Q3 2025. The company reaffirmed FY2026 revenue guidance of $325M-$345M and narrowed adjusted EBITDA guidance to $130M-$140M. Management deferred 2027 DefenCath revenue guidance due to CMS's new quarterly add-on methodology, while noting the Heron asset acquisition (expected to close Q1 2027) should be immediately accretive.

  • Q3 2026 consolidated revenue $54.5M vs $104.3M in Q3 2025 (-48% YoY)
  • DefenCath net sales $17.2M (incl $5M favorable estimate change); Q3 2025 had $104.3M total revenue with 1 month of Melinta
  • GAAP net loss $14.7M ($0.19/share) vs net income $108.6M ($1.42/share) in Q3 2025
  • Adjusted EBITDA $3.1M vs $71.9M in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access